Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side - 2Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 3‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 4Concern for couple jailed in Tehran as British embassy closes
- 5Nine in 10 German industrial firms expect Iran war to hit business
- Humanity is back at the moon! Artemis 2 astronauts arrive in lunar space
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- Japanese H3 rocket fails during launch of navigation satellite (video)
- The Ascent of Rousing Pioneers Who Formed History
- A Time of Careful Eating: Individual Tests in Nourishment
- At least 171 measles cases confirmed in 9 states, CDC data shows
- Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 10 Demonstrated Tips to Boost Your New Android Cell phone: A Thorough Aide
